CN115803316A - 吡啶酮类化合物及其制备方法和应用 - Google Patents

吡啶酮类化合物及其制备方法和应用 Download PDF

Info

Publication number
CN115803316A
CN115803316A CN202180049358.1A CN202180049358A CN115803316A CN 115803316 A CN115803316 A CN 115803316A CN 202180049358 A CN202180049358 A CN 202180049358A CN 115803316 A CN115803316 A CN 115803316A
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049358.1A
Other languages
English (en)
Inventor
程辉敏
温晓明
刘志强
张国刚
魏勇
齐珍珍
牛春意
张佩宇
赖力鹏
马健
温书豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Jingtai Technology Co Ltd
Original Assignee
Shenzhen Jingtai Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Jingtai Technology Co Ltd filed Critical Shenzhen Jingtai Technology Co Ltd
Publication of CN115803316A publication Critical patent/CN115803316A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

本发明公开一种吡啶酮类化合物及其制备方法及应用。具体地，本发明涉及式I化合物，其可用于治疗与肠易激综合征(IBS)和其他胃肠道障碍相关的疾病，以及治疗RET和/或TRK功能性障碍或调节RET和/或TRK活性的癌症、炎症性肠病、神经退行性疾病、慢性疼痛、急性疼痛、炎性疾病、克氏锥虫感染、与骨重建调节失衡有关的疾病。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180049358.1A 2020-07-23 2021-07-23 吡啶酮类化合物及其制备方法和应用 Pending CN115803316A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107197514 2020-07-23
CN202010719751 2020-07-23
PCT/CN2021/108286 WO2022017524A1 (zh) 2020-07-23 2021-07-23 吡啶酮类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115803316A true CN115803316A (zh) 2023-03-14

Family

ID=79728529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049358.1A Pending CN115803316A (zh) 2020-07-23 2021-07-23 吡啶酮类化合物及其制备方法和应用

Country Status (3)

Country Link
CN (1) CN115803316A (zh)
TW (1) TWI786742B (zh)
WO (1) WO2022017524A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
CN107001341A (zh) * 2014-10-16 2017-08-01 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基‑嘧啶衍生物
CN107074768A (zh) * 2014-09-10 2017-08-18 葛兰素史克知识产权发展有限公司 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物
CN107250110A (zh) * 2014-09-10 2017-10-13 葛兰素史克知识产权发展有限公司 作为转染重排(ret)抑制剂的新化合物
CN111343987A (zh) * 2017-11-10 2020-06-26 安杰斯制药公司 作为trk激酶抑制剂之巨环化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
CA2587207A1 (en) * 2004-11-23 2006-06-01 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2009097972A1 (de) * 2008-02-05 2009-08-13 Sanofi-Aventis Sf5-derivate als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
CN107074768A (zh) * 2014-09-10 2017-08-18 葛兰素史克知识产权发展有限公司 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物
CN107250110A (zh) * 2014-09-10 2017-10-13 葛兰素史克知识产权发展有限公司 作为转染重排(ret)抑制剂的新化合物
CN107001341A (zh) * 2014-10-16 2017-08-01 拜耳医药股份有限公司 含有磺亚胺基的氟化苯并呋喃基‑嘧啶衍生物
CN111343987A (zh) * 2017-11-10 2020-06-26 安杰斯制药公司 作为trk激酶抑制剂之巨环化合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HILARY SCHENCK EIDAM ET AL.: "Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS", ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 7, 24 May 2018 (2018-05-24), pages 623 - 628, XP055888343, DOI: 10.1021/acsmedchemlett.8b00035 *
JONATHAN D. MACDONALD ET AL.: "Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5–MYC Protein–Protein Interaction", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 24, 14 November 2019 (2019-11-14), pages 11232 - 11259, XP055888346, DOI: 10.1021/acs.jmedchem.9b01411 *
STEFANO ALTOMONTE ET AL.: "The pentafluorosulfanyl group in cannabinoid receptor ligands: synthesis and comparison with trifluoromethyl and tert-butyl analogues", RSC ADV., vol. 4, 15 April 2014 (2014-04-15), pages 20164 - 20176 *

Also Published As

Publication number Publication date
TW202210460A (zh) 2022-03-16
WO2022017524A1 (zh) 2022-01-27
TWI786742B (zh) 2022-12-11

Similar Documents

Publication Publication Date Title
WO2018086605A1 (zh) 一种含氮大环类化合物、其制备方法、药物组合物及应用
CN105934432A (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
EP4074710A1 (en) Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof
JP2023535746A (ja) Ｃｄｋ７キナーゼ阻害剤として使用される化合物およびその適用
WO2017035753A1 (zh) 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
CN115109078A (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
WO2022188819A1 (zh) Sos1蛋白水解调节剂及其制备方法和应用
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
CN112824420B (zh) 用作egfr激酶抑制剂的化合物及其应用
JP2021501215A (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN113024544A (zh) 一种含氰基并杂环化合物及其用途
CN109071521A (zh) 作为fgfr抑制剂的杂环化合物
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
CN110804059B (zh) 氨基甲酸酯类化合物、药物组合物及其应用
CN110407854B (zh) 新的四环化合物
CN114621256A (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
CN115785154A (zh) 杂芳环化合物及其医药用途
CN115803316A (zh) 吡啶酮类化合物及其制备方法和应用
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
CN116870016B (zh) 杂芳环化合物及其医药用途
CN112020357B (zh) 含吲唑基的三并环类衍生物的盐及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination